// App-Quantinova.ai

617 : Canine transitional cell carcinoma of the bladder expresses activated BRAF, but is not sensitive to vemurafenib

Researchers

Presenter

  • Belen Hernandez

Principal Investigators

  • Kathryn Cronise

  • James C. Costello

  • Rodney Page

  • Susan Lana

  • Kenneth L. Jones

  • Dawn L. Duval

Medical Centers

  • Colorado State University, Fort Collins, CO

  • University of Colorado Anschutz Medical Campus, Aurora, CO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Transitional cell carcinoma of the bladder

  • Bladder Cancer

  • Solid malignancies

  • Melanoma

Biomarkers

  • MutS protein homolog 2

  • Period Circadian Regulator 1

  • EWS RNA Binding Protein 1

  • WRN RecQ Like Helicase

Drug/Treatment

  • Vemurafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved